Last reviewed · How we verify
Basiliximab, Tacrolimus, MMF, Prednisolon
This is a multi-drug immunosuppressive regimen that blocks T-cell activation and proliferation to prevent organ rejection after transplantation.
This is a multi-drug immunosuppressive regimen that blocks T-cell activation and proliferation to prevent organ rejection after transplantation. Used for Prevention of acute organ rejection in kidney transplant recipients, Prevention of acute organ rejection in other solid organ transplantation.
At a glance
| Generic name | Basiliximab, Tacrolimus, MMF, Prednisolon |
|---|---|
| Also known as | Simulect, Advagraf, CellCept, Decortin |
| Sponsor | University Hospital Freiburg |
| Drug class | Immunosuppressive combination regimen |
| Target | IL-2 receptor (basiliximab), calcineurin (tacrolimus), IMPDH (MMF), glucocorticoid receptor (prednisolone) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Transplantation |
| Phase | FDA-approved |
Mechanism of action
Basiliximab is a chimeric monoclonal antibody targeting the IL-2 receptor on T cells, blocking early T-cell activation. Tacrolimus inhibits calcineurin, preventing T-cell cytokine production. Mycophenolate mofetil (MMF) inhibits inosine monophosphate dehydrogenase, selectively suppressing lymphocyte proliferation. Prednisolone is a corticosteroid providing broad immunosuppression. Together, these agents provide multi-target immunosuppression to prevent allograft rejection.
Approved indications
- Prevention of acute organ rejection in kidney transplant recipients
- Prevention of acute organ rejection in other solid organ transplantation
Common side effects
- Infection (bacterial, viral, fungal)
- Nephrotoxicity
- Hyperglycemia
- Hypertension
- Tremor
- Gastrointestinal disturbances
- Malignancy (long-term)
Key clinical trials
- Trial of Steroid Avoidance and Low-dose CNI by ATG-induction in Renal Transplantation (PHASE4)
- 12 Month Athena Study: Everolimus vs. Standard Regimen in de Novo Kidney Transplant Patients (PHASE3)
- Phase IV Study to Evaluate Calcineurin Inhibitor Reduced, Steroid Free Immunosuppression After Renal Transplantation (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: